Two complete responses and response rate of 41% for people with synovial sarcoma reported at ASCO in Adaptimmune's phase 2 SPEARHEAD-1 trial

(Evoke KYNE) Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4), at the American Society of Clinical Oncology (ASCO) congress.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news